FindTrial
Sign In

Investigating the effect of memantine in the prevention of oxaliplatin neuropathy

Investigating the effect of memantine in the prevention of oxaliplatin neuropathy in patient with cancer

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20221219056871N1
Enrollment
64
Registered
2025-01-09
Start date
2023-01-20
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer patients receiving four doses of oxaliplatin.

Interventions

Intervention 1: Intervention group: Patients in the treatment group received memantine at a dose of 5 mg every 12 hours until the day after chemotherapy, and then 10 mg every 12 hours from the second

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: All cancer patients received four doses of oxaliplatin

Exclusion criteria

Exclusion criteria: Those who do not complete the course of treatment or have an underlying disease causing neuropathy

Design outcomes

Primary

MeasureTime frame
Pain. Timepoint: Before and after each course of medicine. Method of measurement: Questionnaire Common Terminology Criteria for Adverse Events 5.;Numbness. Timepoint: Before and after each course of medicine. Method of measurement: Questionnaire Common Terminology Criteria for Adverse Events 5.;Degree of neuropathy. Timepoint: Before and 6 weeks after the end of treatment. Method of measurement: EMG - NCV.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Khalilian

Tehran University of Medical Sciences

a.73khalilian@gmail.com+98 21 6692 3188

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026